Lakefront Biotherapeutics (LKFT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2025, filed Mar 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LKFT SEC filings page.
Lakefront Biotherapeutics (LKFT) reported $1.3B in revenue for fiscal year 2025, up 357.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Lakefront Biotherapeutics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Lakefront Biotherapeutics has an operating margin of 26.5%, meaning the company retains $27 of operating profit per $100 of revenue. Among its peers this margin ranks in the lower range, for a profitability score of 22/100. This is up from -68.3% the prior year.
Lakefront Biotherapeutics's revenue surged 357.5% year-over-year to $1.3B, reflecting rapid business expansion. This strong growth earns a score of 98/100.
With a current ratio of 20.15, Lakefront Biotherapeutics holds $20.15 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 99/100.
Lakefront Biotherapeutics's operations used $302.2M of cash, and capex of $16.1M added to the outflow, for a free cash flow shortfall of $318.2M. This results in a cash flow score of 4/100.
Lakefront Biotherapeutics generates a 9.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 29/100. This is up from 2.6% the prior year.
Lakefront Biotherapeutics scores 7.99, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $2.1B against total liabilities of $200.3M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Lakefront Biotherapeutics passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Lakefront Biotherapeutics used $0.80 of operating cash (-$302.2M OCF vs $376.6M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Lakefront Biotherapeutics earns $285.34 in operating income for every $1 of interest expense ($346.3M vs $1.2M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Lakefront Biotherapeutics generated $1.3B in revenue in fiscal year 2025. This represents an increase of 357.5% from the prior year.
Lakefront Biotherapeutics's EBITDA was $411.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
Lakefront Biotherapeutics reported $376.6M in net income in fiscal year 2025. This represents an increase of 391.1% from the prior year.
Lakefront Biotherapeutics earned $5.72 per diluted share (EPS) in fiscal year 2025. This represents an increase of 393.0% from the prior year.
Cash & Balance Sheet
Lakefront Biotherapeutics recorded an outflow of $318.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Lakefront Biotherapeutics held $103.1M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
Lakefront Biotherapeutics's gross margin was 97.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 10.0 percentage points from the prior year.
Lakefront Biotherapeutics's operating margin was 26.5% in fiscal year 2025, reflecting core business profitability. This is up 94.9 percentage points from the prior year.
Lakefront Biotherapeutics's net profit margin was 28.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2.0 percentage points from the prior year.
Lakefront Biotherapeutics's ROE was 9.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 7.4 percentage points from the prior year.
Capital Allocation
Lakefront Biotherapeutics invested $539.2M in research and development in fiscal year 2025. This represents an increase of 55.3% from the prior year.
Lakefront Biotherapeutics invested $16.1M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 7.1% from the prior year.
Not reported for fiscal year 2025.
LKFT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3B+357.5% | $285.3M+7.6% | $265.2M+2.7% | $258.1M-2.7% | $265.3M-54.6% | $584.7M-37.6% | $937.3M+193.6% | $319.2M+108.9% | $152.8M+11.8% | $136.7M+218.1% | $43.0M |
| Cost of Revenue | $34.9M-3.3% | $36.1M | N/A | $12.9M+600.9% | $1.8M | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $1.3B+409.7% | $249.2M | N/A | $245.2M-6.9% | $263.4M | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $539.2M+55.3% | $347.2M+30.1% | $266.9M-7.5% | $288.6M-20.4% | $362.7M-43.4% | $640.4M+35.8% | $471.6M+30.2% | $362.3M+37.9% | $262.7M+78.4% | $147.3M+4.6% | $140.9M |
| Operating Income | $346.3Mn/m | -$194.9Mn/m | -$97.6Mn/m | -$140.2Mn/m | -$194.2Mn/m | -$218.5M-152.8% | $414.0Mn/m | -$53.9Mn/m | -$108.0Mn/m | -$12.1Mn/m | -$97.1M |
| EBITDA | $411.8Mn/m | -$147.9Mn/m | -$49.4Mn/m | -$70.1M | N/A | -$195.6M-145.7% | $428.0Mn/m | -$48.1Mn/m | -$102.8Mn/m | -$7.7M | N/A |
| Interest Expense | $1.2M+28.7% | $943K-51.8% | $2.0M-73.4% | $7.4M-43.9% | $13.1M+14.3% | $11.5M+706.6% | $1.4M+59.3% | $894K-20.6% | $1.1M+2168.9% | $50K-0.7% | $50K |
| Income Tax | -$21.9Mn/m | -$1.9M-117.6% | $10.6M+1637.8% | $612K-61.1% | $1.6M+4.8% | $1.5Mn/m | -$185K-119.7% | $942K+295.6% | $238K-4.0% | $248Kn/m | -$1.3M |
| Net Income | $376.6M+391.1% | $76.7M-67.3% | $234.2Mn/m | -$233.2Mn/m | -$116.8Mn/m | -$373.5M-322.0% | $168.2Mn/m | -$33.5Mn/m | -$139.1M-344.1% | $57.0Mn/m | -$128.6M |
| EPS (Basic) | $5.72+393.0% | $1.16-67.4% | $3.55n/m | -$3.55n/m | -$1.79n/m | -$5.74-296.5% | $2.92n/m | -$0.64n/m | -$2.81-325.9% | $1.25n/m | -$3.61 |
| EPS (Diluted) | $5.72+393.0% | $1.16-67.4% | $3.55n/m | -$3.55n/m | -$1.79n/m | -$5.74-305.2% | $2.80n/m | -$0.64n/m | -$2.81-333.9% | $1.20n/m | -$3.61 |
| Diluted Shares (Avg) | 66M0.0% | 66M0.0% | 66M+0.3% | 66M | N/A | N/A | N/A | 52M+5.3% | 49M+4.6% | 47M+32.5% | 36M |
Not reported in any period shown, so not listed: SG&A Expenses.
LKFT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.0B-6.6% | $4.3B-11.2% | $4.8B-4.8% | $5.1B-13.8% | $5.9B-15.9% | $7.0B+2.6% | $6.8B+313.2% | $1.6B+6.6% | $1.5B+35.3% | $1.1B+137.9% | $480.5M |
| Current Assets | $3.6B+4.6% | $3.5B-19.1% | $4.3B-5.8% | $4.5B-17.6% | $5.5B-16.2% | $6.6B-0.3% | $6.6B+332.6% | $1.5B+5.7% | $1.4B+35.5% | $1.1B+161.4% | $406.6M |
| Cash & Equivalents | $103.1M+55.1% | $66.5M-64.0% | $184.5M-66.1% | $543.6M-78.5% | $2.5B-3.2% | $2.6B+24.9% | $2.1B+41.3% | $1.5B+6.8% | $1.4B+34.8% | $1.0B+177.9% | $369.5M |
| Inventory | $26.4M-50.2% | $53.0M-35.2% | $81.8M+44.5% | $56.6M+143.2% | $23.3M+52775.4% | $44K-84.6% | $286K-9.5% | $316K-5.7% | $335K+6.0% | $317K-10.3% | $353K |
| Accounts Receivable | $24.3M-50.6% | $49.1M+56.2% | $31.5M-27.2% | $43.3M-65.7% | $126.0M-30.6% | $181.5M+199.4% | $60.6M+184.4% | $21.3M-36.6% | $33.6M+227.5% | $10.3M+140.5% | $4.3M |
| Goodwill | N/A | $72.5M-5.8% | $76.9M+3.0% | $74.7M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $200.3M-84.4% | $1.3B-25.8% | $1.7B-26.9% | $2.4B-18.1% | $2.9B-22.6% | $3.7B+4.0% | $3.6B+1289.2% | $258.0M-21.7% | $329.8M-3.7% | $342.6M+307.0% | $84.2M |
| Current Liabilities | $179.4M-48.3% | $346.8M-26.8% | $473.7M-15.3% | $559.0M-12.8% | $641.1M-17.5% | $776.9M+21.0% | $642.0M+154.8% | $251.9M+22.0% | $206.4M+88.5% | $109.5M+39.3% | $78.6M |
| Non-Current Liabilities | $20.9M-97.8% | $935.4M-25.4% | $1.3B-30.5% | $1.8B-19.7% | $2.2B-23.9% | $2.9B+0.2% | $2.9B+47986.2% | $6.1M-95.0% | $123.3M-47.1% | $233.0M+4105.4% | $5.5M |
| Total Equity | $3.8B+26.6% | $3.0B-3.0% | $3.1B+14.4% | $2.7B-9.7% | $3.0B-8.4% | $3.3B+1.2% | $3.2B+132.1% | $1.4B+14.3% | $1.2B+52.0% | $800.6M+102.0% | $396.4M |
| Retained Earnings | $247.1Mn/m | -$139.0Mn/m | -$252.5Mn/m | -$531.4Mn/m | -$415.6Mn/m | -$409.3Mn/m | -$122.6Mn/m | -$341.1Mn/m | -$254.2Mn/m | -$118.5Mn/m | -$192.5M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Long-Term Debt.
LKFT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$302.2Mn/m | -$331.3Mn/m | -$449.1Mn/m | -$535.5Mn/m | -$570.2Mn/m | -$522.6M-114.5% | $3.6Bn/m | -$163.2Mn/m | -$176.8M-170.0% | $252.6Mn/m | -$124.4M |
| Depreciation & Amortization | $65.6M+39.2% | $47.1M-2.4% | $48.3M-31.2% | $70.1M | N/A | $22.8M+63.5% | $14.0M+140.1% | $5.8M+13.0% | $5.2M+16.7% | $4.4M | N/A |
| Capital Expenditures | $16.1M-7.1% | $17.3M-16.4% | $20.7M-29.4% | $29.3M-52.2% | $61.3M+18.0% | $52.0M+106.9% | $25.1M+111.1% | $11.9M+86.4% | $6.4M+35.8% | $4.7M-29.0% | $6.6M |
| Free Cash Flow | -$318.2Mn/m | -$348.6Mn/m | -$469.8Mn/m | -$564.8Mn/m | -$631.6Mn/m | -$574.6M-116.1% | $3.6Bn/m | -$175.1Mn/m | -$183.1M-173.9% | $247.9Mn/m | -$131.1M |
| Investing Cash Flow | $339.0M+48.4% | $228.3M+190.0% | $78.7Mn/m | -$1.3B-317.5% | $612.6M-33.9% | $926.2Mn/m | -$4.2Bn/m | -$18.2Mn/m | -$660Kn/m | -$7.7Mn/m | -$4.7M |
| Financing Cash Flow | -$3.8Mn/m | -$5.1Mn/m | -$5.5Mn/m | -$1.6Mn/m | -$4.4M-116.3% | $27.0M-98.2% | $1.5B+354.7% | $329.8M-22.4% | $424.8M+1.7% | $417.9M+41.8% | $294.7M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
LKFT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 97.3%+10.0pp | 87.4% | N/A | 95.0%-4.3pp | 99.3% | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 26.5%+94.9pp | -68.3%-31.5pp | -36.8%+17.5pp | -54.3%+18.9pp | -73.2%-35.8pp | -37.4%-81.5pp | 44.2%+61.1pp | -16.9%+53.8pp | -70.7%-61.8pp | -8.9% | -226.1% |
| Net Margin | 28.8%+2.0pp | 26.9%-61.4pp | 88.3%+178.7pp | -90.4%-46.3pp | -44.0%+19.9pp | -63.9%-81.8pp | 17.9%+28.4pp | -10.5%+80.5pp | -91.0%-132.7pp | 41.7% | -299.3% |
| Return on Equity | 9.9%+7.4pp | 2.6%-5.0pp | 7.6%+16.2pp | -8.6%-4.7pp | -3.9%+7.5pp | -11.4%-16.7pp | 5.2%+7.6pp | -2.4%+9.0pp | -11.4%-18.6pp | 7.1%+39.6pp | -32.4% |
| Return on Assets | 9.4%+7.6pp | 1.8%-3.1pp | 4.9%+9.5pp | -4.6%-2.6pp | -2.0%+3.4pp | -5.3%-7.8pp | 2.5%+4.5pp | -2.0%+7.0pp | -9.0%-14.0pp | 5.0%+31.8pp | -26.8% |
| Current Ratio | 20.15+10.2x | 9.97+0.9x | 9.02+0.9x | 8.11-0.5x | 8.58+0.1x | 8.45-1.8x | 10.26+4.2x | 6.04-0.9x | 6.98-2.7x | 9.70+4.5x | 5.17 |
| Liabilities-to-Equity | 0.05-0.4x | 0.43-0.1x | 0.56-0.3x | 0.87-0.1x | 0.96-0.2x | 1.140.0x | 1.11+0.9x | 0.19-0.1x | 0.27-0.2x | 0.43+0.2x | 0.21 |
| Asset Turnover | 0.33+0.3x | 0.070.0x | 0.060.0x | 0.050.0x | 0.050.0x | 0.08-0.1x | 0.14-0.1x | 0.19+0.1x | 0.100.0x | 0.120.0x | 0.09 |
| FCF Margin | -24.4% | -122.2% | -177.2% | -218.8% | -238.1% | -98.3% | 381.6% | -54.9% | -119.9% | 181.4% | -305.1% |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Where Lakefront Biotherapeutics Ranks
Frequently Asked Questions
What is Lakefront Biotherapeutics's annual revenue?
Lakefront Biotherapeutics (LKFT) reported $1.3B in total revenue for fiscal year 2025. This represents a 357.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Lakefront Biotherapeutics's revenue growing?
Lakefront Biotherapeutics (LKFT) revenue grew by 357.5% year-over-year, from $285.3M to $1.3B in fiscal year 2025.
Is Lakefront Biotherapeutics profitable?
Yes, Lakefront Biotherapeutics (LKFT) reported a net income of $376.6M in fiscal year 2025, with a net profit margin of 28.8%.
What is Lakefront Biotherapeutics's EBITDA?
Lakefront Biotherapeutics (LKFT) had EBITDA of $411.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Lakefront Biotherapeutics's gross margin?
Lakefront Biotherapeutics (LKFT) had a gross margin of 97.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Lakefront Biotherapeutics's operating margin?
Lakefront Biotherapeutics (LKFT) had an operating margin of 26.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Lakefront Biotherapeutics's net profit margin?
Lakefront Biotherapeutics (LKFT) had a net profit margin of 28.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Lakefront Biotherapeutics's return on equity (ROE)?
Lakefront Biotherapeutics (LKFT) has a return on equity of 9.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Lakefront Biotherapeutics's free cash flow?
Lakefront Biotherapeutics (LKFT) recorded an outflow of $318.2M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Lakefront Biotherapeutics's operating cash flow?
Lakefront Biotherapeutics (LKFT) recorded an outflow of $302.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Lakefront Biotherapeutics's total assets?
Lakefront Biotherapeutics (LKFT) had $4.0B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Lakefront Biotherapeutics's capital expenditures?
Lakefront Biotherapeutics (LKFT) invested $16.1M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Lakefront Biotherapeutics spend on research and development?
Lakefront Biotherapeutics (LKFT) invested $539.2M in research and development during fiscal year 2025.
What is Lakefront Biotherapeutics's current ratio?
Lakefront Biotherapeutics (LKFT) had a current ratio of 20.15 as of fiscal year 2025, which is generally considered healthy.
What is Lakefront Biotherapeutics's liabilities-to-equity ratio?
Lakefront Biotherapeutics (LKFT) had a liabilities-to-equity ratio of 0.05 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Lakefront Biotherapeutics's return on assets (ROA)?
Lakefront Biotherapeutics (LKFT) had a return on assets of 9.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Lakefront Biotherapeutics's P/E ratio?
Lakefront Biotherapeutics (LKFT) trades at 5.5x earnings, its market capitalization divided by $376.6M net income, FY2025. The market capitalization is $2.1B as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Lakefront Biotherapeutics's price-to-sales ratio?
Lakefront Biotherapeutics (LKFT) trades at 1.6x sales, its market capitalization divided by $1.3B revenue, FY2025. The market capitalization is $2.1B as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Lakefront Biotherapeutics's Altman Z-Score?
Lakefront Biotherapeutics (LKFT) has an Altman Z-Score of 7.99, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Lakefront Biotherapeutics's Piotroski F-Score?
Lakefront Biotherapeutics (LKFT) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Lakefront Biotherapeutics's earnings high quality?
For every $1 of reported earnings, Lakefront Biotherapeutics (LKFT) used $0.80 of operating cash (-$302.2M OCF vs $376.6M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Lakefront Biotherapeutics cover its interest payments?
Lakefront Biotherapeutics (LKFT) has an interest coverage ratio of 285.34x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Lakefront Biotherapeutics?
Lakefront Biotherapeutics (LKFT) scores 56 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.